25 results about "Succinate dehydrogenase" patented technology

A combination including a dithiocarbamate fungicide, a succinate dehydrogenase fungicide and at least one of ergosterol biosynthesis inhibitor fungicide or a quinone outside inhibitor fungicide.

The invention relates to the technical field of spectrum detection of pesticide residues, and discloses a succinate dehydrogenase pesticide residue screening method. The method comprises the following steps: carrying out feature standardization processing on a multi-source spectral data set, unifying feature dimensions of each spectral source, removing feature conflict dimensions, and carrying out duplicate removal to obtain an integrated spectral data set; extracting a pesticide residue characteristic field, a spectral absorption peak field and a pesticide category field, and segmenting data characteristics to generate a characteristic screening data set; mapping the original absorption peak and the target absorption peak to a standard spectral coordinate system to generate a spectral feature distribution map; classifying and aggregating spectral absorption behaviors according to pesticide categories, evaluating absorption activeness of different categories of pesticides in a specific characteristic period of a target spectral region, and generating a classification trend index. The method can solve the problems of difficult integration of multi-source spectral data, inaccurate feature extraction and the like, and improves the consistency and accuracy of screening.

The invention relates to a fungicidal composition comprising: choline pelargonate and an active ingredient selected from the group consisting of a quinone outside inhibitor (QoI), a succinate dehydrogenase inhibitor (SDHI), an oxysterol binding protein homologue inhibitor (OSBPI), a demethylation inhibitor (DMI), and a copper-containing compound. The invention also concerns a method for treating a fungal disease on a plant or a part thereof, the method comprising applying a fungicidal composition comprising choline pelargonate and one or more active ingredients selected from the group consisting of a quinone outside inhibitor (QoI), a succinate dehydrogenase inhibitor (SDHI), an oxysterol binding protein homologue inhibitor (OSBPI), a demethylation inhibitor (DMI), and a copper-containing compound to the plant, part thereof, or locus of growth of the plant.

The invention discloses a novel chiral succinate dehydrogenase inhibitor and application thereof, and belongs to the field of pesticide chemistry. The compound shown in the formula (I) is obtained by modifying a fluxapyroxad structure, and an aniline group of fluxapyroxad is mainly replaced by a cyclohexylamine group with a chiral structure. The antibacterial activity of the compound is improved, and the compound can play a better role in preventing and controlling fungal diseases of plants, so that the yield and quality of crops are improved, the application amount of pesticides is reduced, environmental pollution and ecological damage are reduced, and the problems of pesticide resistance and the like are solved. # imgabs0 # is represented by formula (I).

The present invention relates to an emulsion concentrate (EC) formulation of succinate dehydrogenase inhibitor fungicides, the manufacture of such a formulation, and the use of its diluted form for the control of fungal pathogens, in particular in crops of useful plants. More specifically, the present invention relates to an emulsion concentrate of-difluoromethyl-1-methyl-1H-pyrazol-4-methoxyl-[1-methyl-2-(2, 4, 6-trichlorophenyl)-ethyl]-amide comprising a blend of at least three surfactants and an aromatic ester solvent.

The invention belongs to the technical field of gene engineering, and discloses identification of strawberry powdery mildew succinate dehydrogenase related gene SDHB nucleotide point mutation and application of the strawberry powdery mildew succinate dehydrogenase related gene SDHB nucleotide point mutation in SDHI bactericide resistance monitoring. The invention specifically discloses a molecular detection method for identifying the drug resistance of the base mutation of the strawberry powdery mildew SDHB gene to SDHI bactericides and a special primer thereof. The molecular detection method provided by the invention is high in sensitivity, good in stability and short in detection period, and can be used for monitoring the resistance gene frequency of strawberry powdery mildew to SDHI fungicides and the occurrence and development conditions of resistance in a high-throughput manner.

The invention relates to an application of a succinate dehydrogenase subunit SDHC protein and a coding gene thereof in preparation of a medicine for preventing and / or treating renal fibrosis, and belongs to the field of biological medicines. The invention proposes and verifies that SDHC gene delivery can alleviate kidney pathological changes of chronic kidney diseases for the first time; the expression level of kidney tissue fibrosis related indexes is reduced; the transdifferentiation of renal tubular epithelial cells to myofibroblasts is inhibited. SDHC gene delivery can achieve the effect of improving the chronic kidney disease, and good development and application prospects are achieved.

The present invention provides fungicidal combination comprising: (i) an amount of a compound of Formula Iand (ii) an amount of at least two fungicides (A) and (B) selected from the group consisting of strobilurins, succinate dehydrogenase-inhibitors (SDHI), azoles and multi-sites inhibitors.

The invention discloses a 2-[2-(thiophenyl) benzothiazole-6-yl] acetamide compound with antimicrobial activity and / or pharmaceutically acceptable salt and application thereof, and relates to the technical field of chemical and pesticide chemical development. The 2-[2-(thiophenyl) benzothiazole-6-yl] acetamide compound with antimicrobial activity and / or the pharmaceutically acceptable salt thereof provided by the invention are / is obtained by carrying out structure optimization on the basis of benzothiazole active compounds in black ants. The compound provided by the invention has a certain inhibition effect on plant pathogenic fungi and animal pathogenic bacteria, and realizes broad-spectrum antimicrobial activity by inhibiting succinate dehydrogenase (SDH), and an acute toxicity test shows that the compound is good in safety. The 2-[2-(thiophenyl) benzothiazole-6-yl] acetamide compound with antimicrobial activity and / or the pharmaceutically acceptable salt thereof provided by the invention can be prepared into a bactericidal pesticide, and can also be used as a structure precursor of an antituberculosis drug.

A combination comprising a multi-site contact fungicide, a succinate dehydrogenase inhibitor fungicide and a second systemic fungicide and a method using the same.

This invention belongs to the field of biomedical technology, specifically relating to compounds for treating KRAS-mutant tumors and their uses. This invention provides compound 666-15, which provides dual inhibition of cytoplasmic-mitochondrial NAD5. + Transport (via targeting SLC25A51) and succinate dehydrogenase (SDH / complex II), while simultaneously disrupting mitochondrial NAD. + Transport and respiratory chain NAD + A novel therapeutic strategy to target KRAS-mutant tumors by utilizing regenerative functions.

Provided herein are methods of treating diseases, disorders, or conditions associated with succinate dehydrogenase (SDH) deficiency using a multi-target tyrosine kinase inhibitor (TKI). Also provided herein are methods of treating diseases using a multi-target TKI in combination with a Bcl-2 inhibitor.

A combination comprising a dithiocarbamate fungicide, a succinate dehydrogenase fungicide and at least one of ergosterol biosynthesis inhibitor fungicide or a quinone outside inhibitor fungicide.

A combination comprising a multi-site contact fungicide, a succinate dehydrogenase inhibitor fungicide and a second systemic fungicide and a method using the same.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a succinate dehydrogenase complex B subunit SDHB as a therapeutic target to preparation of drugs for screening and preventing and / or treating aortic valve calcification. The invention proves that the ROR alpha agonist has a protective effect on CAVD through an SDHB-mediated mechanism. In short, succinic acid in the calcified aortic valve is metabolized and accumulated, and in-vitro supplementation of succinic acid promotes osteogenesis and calcification of aortic valve interstitial cells (h-VICs); the overexpression of ROR alpha improves the abnormal mitochondrial metabolism of h-VICs; sDHB is intervened to counteract aortic valve calcification mediated by the ROR alpha agonist to abnormal mitochondrial metabolism. Therefore, as a potential therapeutic target for aortic valve calcification, SDHB can be used for screening and preparing drugs for treating or preventing CAVD, and the technical problem that treatment can only be carried out through a valve replacement operation at present, and an effective drug treatment means is lacked is solved.

A combination comprising a multi-site contact fungicide, a succinate dehydrogenase inhibitor fungicide and a second systemic fungicide and a method using the same.

The present application provides a kind of derivative of dual-target inhibitor structure, the compound has the structure of formula (I) as shown in formula (I): formula (I) wherein, in formula (I) R1 It is selected from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-trifluoromethylphenyl, 4-methylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 4-nitrophenyl, 4-methylsulfonylphenyl, thienyl, pyridyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 3,4,5-trifluorophenyl;R2 It is selected from H, halogen, trifluoromethyl, R2 It is in arbitrary position substitution position, single substitution or multiple substitution.The present application uses the derivative of the dual-target inhibitor structure for the use of the agent for preventing and treating plant pathogenic fungi.It can be seen that it has inhibitory effect on various plant fungi, and the inhibitory effect in sclerotinia is more significant.It has significant inhibitory effect on succinate dehydrogenase and chitin synthase activity.

The present invention relates to a synergistically effective fungicidal composition comprising, as component (A), a fungicidally active amount of choline phosphonate and, as component (B), at least one additional fungicide selected from the group comprising quinone fungicides, succinate dehydrogenase inhibitors, benzamide fungicides, sulfur fungicides, carboxylic acid amide fungicides, demethylation inhibitor fungicides, phenylamide fungicides, copper fungicides, piperidinyl thiazol isoxazoline fungicides, and sugar alcohols, wherein the weight ratio of components (A) and (B) is in the range of 1:1000 to 1000:1. The invention further relates to a kit for using the fungicidal composition according to the invention in an amount effective for controlling one or more types of fungal infections by applying the fungicidal composition to the fungal infections.

The invention relates to application of a succinate dehydrogenase subunit B (SDHB) in preparation of a medicine for preventing and / or treating renal fibrosis, and belongs to the technical field of medicine and biology. Based on research of the invention, the expression level of SDHB in renal fibrosis tissue is significantly reduced, and enhancement of the expression or activity of SDHB can effectively improve the function of renal tubular epithelial cells and alleviate the fibrosis process. By improving the expression or activity of SDHB, the oxidative phosphorylation ability of mitochondria can be enhanced, the energy metabolism state of cells can be improved, and the generation of active oxygen can be reduced, so that the occurrence and development of renal cell injury and fibrosis can be prevented. According to the application disclosed by the invention, SDHB is determined as a new target spot for resisting renal fibrosis for the first time, and a new direction is provided for prevention and treatment of renal fibrosis.

A combination including a dithiocarbamate fungicide, a succinate dehydrogenase fungicide and at least one of ergosterol biosynthesis inhibitor fungicide or a quinone outside inhibitor fungicide.

The present disclosure relates to fungicidal combinations, compositions including the fungicidal combinations, and to a method of controlling fungal diseases using the combinations. The combination includes at least one demethylation inhibitor; at least one succinate dehydrogenase (SDH) inhibitor; at least one RNA polymerase I inhibitor; and at least one ß-tubulin assembly inhibitor and / or at least one multi-site fungicide.

The evidences provided by the present patent application demonstrate the therapeutic effect of succinate dehydrogenase inhibition to counteract the cardiotoxicity of chemotherapies used in cancer, such as acute myeloid leukemia and breast cancer. This combination also remarkably exhibits a chemosensitizing capacity of cancer cells. The use of Malonate in patients affected by these pathologies would therefore protect the heart from the toxic side effects of chemotherapy and eliminate the most resistant cells for an ever better risk-benefit ratio for these patients. Accordingly, the present invention relates to a method for the treatment of chemotherapy-induced cardiotoxicity in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a succinate dehydrogenase inhibitor.

A genetically engineered microorganism for producing succinate, including: a host cell derived from a methylotrophic bacterium. The host cell has an ethylmalonyl-CoA pathway. The activity of succinate dehydrogenase in the methylotrophic bacterium is reduced or inactivated, and the genetically engineered microorganism is capable of growing using methanol as the sole carbon source and producing succinate. Also provided herein are methods for producing succinate and methods for making genetically engineered microorganisms for producing succinate.

This invention aims to provide a method for preparing bis(4-pyrazolone)methane compounds. The preparation method is as follows: a mixture of compound A and compound B is added to an organic mixed solvent, heated under reflux at a certain temperature for 4-6 hours, then filtered while hot. The filtrate is allowed to evaporate the solvent naturally at room temperature to obtain the final target product C. R1, R2, R3, R4, and R5 are any one of alkyl, aryl, heterocyclic, or hydrogen atoms, respectively. The method for preparing bis(4-pyrazolone)methane compounds provided by this invention requires fewer raw materials, has simpler synthesis steps, milder reaction conditions, and higher yield than traditional methods. These compounds have the ability to improve the growth rate of edible fungi mycelia and activate the activity of mycelial succinate dehydrogenase, and can be used as potential growth regulators for edible fungi.

The invention relates to the field of diagnosis and treatment of skin injury caused by ultraviolet rays, in particular to succinate dehydrogenase (SDH) serving as a marker of the skin injury caused by the ultraviolet rays and application of the succinate dehydrogenase (SDH) to preparation of a treatment medicine. The activity of SDH in skin tissues and cells is remarkably reduced due to ultraviolet irradiation, so that macrophages are promoted to be polarized to M1 type, and inflammatory response is aggravated. The SDH activity is detected, so that the SDH can be used as an effective marker for diagnosing and monitoring skin injury caused by ultraviolet rays. Through overexpression of SDH subunit A or use of a TRAP1 inhibitor DN401, SDH activity can be recovered, macrophage M1 polarization can be inhibited, and skin erythema, edema and the like caused by ultraviolet rays can be significantly relieved. The invention provides a new diagnosis and treatment strategy, effectively prevents and treats skin injury caused by ultraviolet rays by intervening SDH activity, and has a remarkable clinical application prospect.